title: Synergetic protective effects of combined blockade by two kinds of autolesion mediator receptor on neurological function after cervical cord injury.
abstract: OBJECTIVE
  To investigate the effects of combined blockade by platelet activating factor (PAF) receptor antagonist BN52021 in combination with opiate receptor antagonist naloxone on neurological function and neurological tissue damage after cervical cord injury.
  
  
  METHODS
  Spinal cord contusion at C6 segment was made with Allen method in cats, which were randomly divided into four groups: saline control group; BN52021 group; naloxone group; and combined treatment group with BN52021 and naloxone. Alteration of cervical cord blood flow, blood barrier permeability of the spinal cord, cervical cord tissue pathology and neurological functional scores were studied after experimental cervical cord injury.
  
  
  RESULTS
  The animals treated with BN52021 or naloxone had significantly better functional scores than saline controls 6 weeks after injury (P < 0.05). Moreover, the combined treatment showed significantly better neurologic recovery than either naloxone or BN52021 treated animals (P < 0.05). The other indexes in combined treatment animals were also superior to those in naloxone or BN52021 treated animals.
  
  
  CONCLUSIONS
  Combined blockade by two kinds of autolesion mediator receptor can more effectively inhibit secondary damage production and development after cervical cord injury and improve neurologic function.
authors.affiliation: Department of Orthopaedics, Changzheng Hospital, Second Military Medical College University, Shanghai, China.
authors.forename: J
authors.initials: J
authors.lastname: Xiao
authors.forename: D
authors.initials: D
authors.lastname: Zhao
authors.forename: T
authors.initials: T
authors.lastname: Hou
authors.forename: K
authors.initials: K
authors.lastname: Wu
authors.forename: H
authors.initials: H
authors.lastname: Zeng
mesh_terms: D000818:Animals; D002415:Cats; D004224:Diterpenes; D004357:Drug Synergism; D046934:Ginkgolides; D007783:Lactones / Q000494:pharmacology*; D008297:Male; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors*; D011897:Random Allocation; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; D013116:Spinal Cord / Q000473:pathology / Q000503:physiopathology; D013119:Spinal Cord Injuries / Q000473:pathology* / Q000503:physiopathology
chemical_list: D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones; D009292:Narcotic Antagonists; D010972:Platelet Activating Factor; D010980:Platelet Membrane Glycoproteins; D011956:Receptors, Cell Surface; D043562:Receptors, G-Protein-Coupled; C039351:platelet activating factor receptor; D009270:Naloxone; C045856:ginkgolide B